Novartis and Pfizer Join Forces to Treat Nonalcoholic Steatohepatitis
rawpixel / Pixabay

Novartis and Pfizer Join Forces to Treat Nonalcoholic Steatohepatitis

According to a story from globenewswire.com, the drug developers Pfizer and Novartis have recently announced the beginning of a collaborative effort to test new potential therapies for nonalcoholic steatohepatitis (NASH).…

Continue Reading Novartis and Pfizer Join Forces to Treat Nonalcoholic Steatohepatitis

Preliminary Phase I Trial Data Released For Experimental Gastronintestinal Stromal Tumor Drug

According to a story from BioPortfolio, the biopharmaceutical company Deciphera Pharmaceuticals, Inc., recently announced the release of preliminary data from the company's Phase I clinical trial, which is still in…

Continue Reading Preliminary Phase I Trial Data Released For Experimental Gastronintestinal Stromal Tumor Drug
Should Medicine Stop Focusing on Individual Diseases and Start Treating Combinations of Conditions?
rawpixel / Pixabay

Should Medicine Stop Focusing on Individual Diseases and Start Treating Combinations of Conditions?

Multimorbidity, typically defined as having two or more long-term health conditions, has become a topic of increasing focus for healthcare providers. Many elderly people are affected by multimorbidity, with the…

Continue Reading Should Medicine Stop Focusing on Individual Diseases and Start Treating Combinations of Conditions?
FDA Approves Investigational New Drug Application For an Experimental Treatment for Guillain-Barre Syndrome
RobinHiggins / Pixabay

FDA Approves Investigational New Drug Application For an Experimental Treatment for Guillain-Barre Syndrome

According to a story from BioSpace, the biotechnology company Cellenkos, Inc., recently announced that the US Food and Drug Administration (FDA) has given the company the go ahead to begin…

Continue Reading FDA Approves Investigational New Drug Application For an Experimental Treatment for Guillain-Barre Syndrome